THE WIRE · № 60876
SAS, NC State Launch AI Think & Do Tank to Advance Health Research
01 THE MACHINE READ
WHY IT MATTERS.
A university-industry AI research partnership signals continued corporate investment in applied AI for drug discovery, but no financial terms or near-term revenue impact are disclosed.
Corporate AI-health partnerships keep expanding without disclosed economics
Publication of research results or commercial spinouts
Partnership may yield no commercializable output
FULL DISPATCH
Research partnership applies data and AI to speed the path to new treatments and strengthen nutrition and environmental resilience CARY, N.C., Oct. 1, 2026 /PRNewswire/ -- Fifty years after SAS grew out of an agricultural research project at North Carolina State University, the two...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.